Last reviewed · How we verify
NCT07113847
Effectiveness of Resin-Based Desensitizer and Laser, Compared to Fluoride Varnish in Management of Dentine Hypersensitivity in Non-carious Cervical Lesions
Phase 2, PHASE3 trial testing Resin-Based Desensitizer in Dentin Hypersensitivity, Non-carious Cervical Lesions, Bioactive Glass Air Polishing, S-PRG in 84 participants. Participants enrolled and being followed up; not accepting new ones.
1 October 2025
Quick facts
| Lead sponsor | British University In Egypt |
|---|---|
| Phase | Phase 2, PHASE3 |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 84 |
| Start date | 1 April 2025 |
| Primary completion | 1 October 2025 |
| Estimated completion | 30 October 2025 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- Resin-Based Desensitizer — full drug profile →
- Laser Desensitizer
- Fluoride-Based Desensitizer — full drug profile →
Conditions studied
- Dentin Hypersensitivity, Non-carious Cervical Lesions, Bioactive Glass Air Polishing, S-PRG — all drugs for Dentin Hypersensitivity, Non-carious Cervical Lesions, Bioactive Glass Air Polishing, S-PRG →
- Dentin Hypersensitivity — all drugs for Dentin Hypersensitivity →
- Dentin Desensitizing Agents — all drugs for Dentin Desensitizing Agents →
- Desensitization — all drugs for Desensitization →
Sponsor
British University In Egypt
Who can join
Adults 18 to 50, any sex, with Dentin Hypersensitivity, Non-carious Cervical Lesions, Bioactive Glass Air Polishing, S-PRG or Dentin Hypersensitivity. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
84 patients who fulfill the inclusion criteria will be enrolled to the study. For every patient a tooth of complain which fulfill the inclusion criteria will be selected, so the total number of included teeth will be 84 teeth. Teeth will be classified into 4 groups according to the type of desensitizer used. Where in group 1 (G1) patients will be randomly assigned to "Resin-Based Desensitizer", in group 2 (G2) patients will be randomly assigned to "Laser Desensitizer", in group 3 (G3) patients will be randomly assigned to "Combination of Laser + Resin-Based Desensitizer", and in group 4 (G4) patients will be randomly assigned to "Fluoride-Based Desensitizer". For every patient, sensitivity test will be done using visual analogue scale immediately after application, three months after application and six months after application. Table 1 shows the variables of the study, and Table 2 shows the variables of the study. Each patient's name will be replaced with a case number within the group to protect the privacy of medical information and data of the patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07113847
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other British University In Egypt trials
Trials by the same sponsor.
- NCT07492576 — Evaluation of the Magnesium Shield Compared to Dual Zone Grafting Approach in Immediate Implant Site Management · NA · recruiting
- NCT07457749 — Clinical Performance of a Novel Self-cured Resin Composite Compared to a Light-cured Bioactive Resin Composite Restorati · EARLY_PHASE1 · recruiting
- NCT07368621 — Effectiveness of Connective Tissue Graft With and Without Leukocyte Platelet Rich Fibrin on Peri-implant Soft Tissue Thi · NA · recruiting
- NCT07480070 — Two-Year Clinical Performance of Self-Cured Resin Composite in Comparison to Light-Cured Bioactive Resin Composite in Re · NA · completed
- NCT07115758 — Vestibular Versus Trapezoid Flap in Immediate Implants · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07113847 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by British University In Egypt
- Last refreshed: 13 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07113847.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing